Limitless Possibilities
Through Exquisite Control

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body’s first line of immunological response and an essential component of immune function.
Discover Our Mission arrow-button

Regulating
Immune Response

Serious diseases can result if the immune system consistently under- or over-responds. Our first-in-class medicines precisely control immune responses in patients with inflammatory or autoimmune disorders, and enhance responses in patients with cancer.

Explore Our Approach arrow-button

A Leading Portfolio of
First-in-Class Small Molecules

We are working with urgency to develop novel drugs that meet the needs of patients with inflammatory disorders and cancer.

View Our Pipeline arrow-button

Experts with an Unprecedented Track Record

Since the inception of IFM, we have advanced multiple, novel programs from discovery to first-in-human studies and beyond.

The IFM Team Has an Unprecedented Track Record

Among the team's achievements in the company's first 3.5 years has been the progression of 3 novel programs from the standing start through to the clinic and the closing of 2 major deals.

2015

Arrow-right
October

IFM founded by G. Glick and seed-financed by Atlas Venture to discover agonists of NLRP3 for cancer.

2016

Arrow-right
FEBRUARY

Novel and proprietary NLRP3 agonist leads identified

MAY

Novel and proprietary STING agonists discovered

JUNE

IFM's $27M Series A closed

2017

Arrow-right
SEPTEMBER

Preclinical PoC for both NLRP3 and STING agonists demonstrated

SEPTEMBER

$2.32B sale of IFM Uno to BMS closed; IFM Therapeutics, LLC created as a spin-out, and IFM Tre launched

2018

Arrow-right
FEBRUARY

BMS dosed initial patient with first-in-class NLRP3 agonist, IFM-1222

JULY

IFM Tre's $31M Series A financing closed (focus on NLRP3 antagonist)

2019

Arrow-right
FEBRUARY

IFM Due launched (focus on cGAS/STING antagonists)

MARCH

IFM Tre dosed initial subject with first-in-class NLRP3 antagonist, IFM-2427

APRIL

BMS dosed first patient with STING agonist, IFM-1364

MAY

$1.575B sale of IFM Tre to Novartis closed

Recent Updates

View All Updates arrow-button